For instance, FGFR4, a target of autoantibodies with significant diagnostic ability for CRC, has been reported to be druggable using CRC cells with either broad-spectrum kinase inhibitors like TKI-258 or more selective FGFR inhibitors like PD173074, or specific antibody inhibitors in phase III (128, 192). The gene discussed is FGFR4; the disease is colorectal carcinoma.